4-氯-2-甲基嘧啶-5-甲酸乙酯 | 2134-36-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-2-甲基嘧啶-5-甲酸乙酯
• 中文别名: 4-氯-2-甲基嘧啶-5-羧酸乙酯(2-甲基-4-氯嘧；4-氯-2-甲基嘧啶-5-羧酸乙酯(2-甲基-4-氯嘧啶-5-羧酸乙酯)；4-氯-2-甲基嘧啶-5-羧酸乙酯；2-甲基-4-氯嘧啶-5-羧酸乙酯
• 英文名称: ethyl 4-chloro-2-methylpyrimidine-5-carboxylate
• 英文别名: ethyl-2-methyl-4-chloropyrimidine-5-carboxylate；ethyl 4-chloro-2-methyl-5-pyrimidinecarboxylate；4-chloro-2-methyl-pyrimidine-5-carboxylic acid ethyl ester；4-Chlor-2-methyl-pyrimidin-5-carbonsaeure-aethylester；ethyl 2-methyl-4-chloropyrimidine-5-carboxylate；4-Chlor-2-methyl-5-aethoxycarbonyl-pyrimidin
• CAS: 2134-36-3
• 化学式: C₈H₉ClN₂O₂
• 分子量: 200.625
• InChiKey: LXIAVLIGRIDNHQ-UHFFFAOYSA-N

物化性质

• 熔点：
  31 °C
• 沸点：
  276℃
• 密度：
  1.265
• 闪点：
  121℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-chloro-2-methylpyrimidine-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-chloro-2-methylpyrimidine-5-carboxylate
CAS number: 2134-36-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9ClN2O2
Molecular weight: 200.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-2-甲基嘧啶-5-甲酸乙酯 在 甲酸 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 ethyl 2-methyl-4-[N-butyl-N-{(2'-[1H-tetrazol-5-yl]biphenyl-4-yl)methyl}amino]pyrimidine-5-carboxylate
  参考文献：
  名称：

  2-（烷基氨基）烟酸及其类似物。强大的血管紧张素II拮抗剂。

  摘要：

  人们发现，通过-CH2-NR'-连接（1）连接到联苯四唑的一系列吡啶和其他六元环杂环是有效的血管紧张素II拮抗剂。在嘧啶羧酸系列中（W = CR，X = N，Y = CH，Z = COOH），环外氮上带有烷基（R'）的化合物比带有烷基（R）的化合物更有效在杂环上。相应的吡啶，哒嗪，吡嗪和1,2,4-三嗪羧酸也显示出有效的体外血管紧张素II拮抗作用。吡啶（W，X，Y = CH，Z = COOH，R'= n-C3H7）具有很强的体外活性（pA2 = 10.10，兔主动脉，Ki = 0.61 nM，大鼠肝脏中的受体结合）以及出色的口服降压活性和生物利用度。

  DOI：

  10.1021/jm00070a012
• 作为产物：
  描述：

  2-甲基-6-羟基嘧啶甲酸乙酯 在 三氯氧磷 作用下， 反应 2.0h， 生成 4-氯-2-甲基嘧啶-5-甲酸乙酯
  参考文献：
  名称：

  一系列新的作为肾素抑制剂的N-（哌啶-3-基）嘧啶-5-羧酰胺的结构设计

  摘要：

  天冬氨酰蛋白酶肾素的作用是肾素-血管紧张素-醛固酮系统的限速起始步骤。因此，肾素是血压以及心血管和肾脏疾病的发作和发展的特别有希望的靶标。设计新的嘧啶衍生物5 – 14是为了增强化合物3的肾素抑制活性，这种化合物是通过我们以前的基于片段的药物设计方法确定的。引入对于在催化位点与两种天冬氨酸相互作用必不可少的碱性胺，并优化S1 / S3结合元素，包括通过Leu114诱导拟合的结构改变（Leu114由“ Leu-in”变为“ Leu-out”）。基于合理结构的药物设计方法导致了N的发现-（piperidin-3-yl）pyrimidine-5-carboxamide 14，比化合物3强65,000倍的有效肾素抑制剂。出人意料的是，化合物14的抑制活性的这种显着增强已经通过仅向化合物3整体添加七个重原子而实现。化合物14在大鼠中显示出优于其他天冬氨酰蛋白酶的优异选择性和中等的口服生物利用度。

  DOI：

  10.1016/j.bmc.2016.09.030

文献信息

• SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Luzzio Michael Joseph

  公开号：US20090054395A1

  公开（公告）日：2009-02-26

  The present invention relates to a compound of the formula I wherein R 1 to R 6 , A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本发明涉及一种具有以下式I的化合物 其中R 1 至R 6 ，A，B，n和m如本文所定义。这种新型磺酰胺衍生物在治疗哺乳动物（如癌症）中的异常细胞生长方面是有用的。本发明还涉及一种在治疗哺乳动物（尤其是人类）中的异常细胞生长中使用这种化合物的方法，以及含有这种化合物的药物组合物。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：GENENTECH, INC.

  公开号：US20150031674A1

  公开（公告）日：2015-01-29

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , R c , R d , R e , n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
• INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
  申请人：Bifulco, JR. Neil

  公开号：US20150197519A1

  公开（公告）日：2015-07-16

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

  本处描述的是FGFR-4的抑制剂，包括含有此类化合物的药物组合物，以及使用此类化合物和组合物来抑制FGFR-4活性的方法。
• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• HETEROCYCLIC COMPOUND HAVING ANTI-HIV ACTIVITY
  申请人：Toyama Chemical Co., Ltd.

  公开号：EP2810944A1

  公开（公告）日：2014-12-10

  A heterocyclic compound represented by the general formula (in the formula, R1, R2 and R3 may be the same or different, and each represents a hydrogen atom, a halogen atom, or this general formula (X1-Y1-R4) (in the formula: X1 represents this general formula (NR5) (in the formula, R5 represents a hydrogen atom, etc.) or the like; Y1 represents an optionally substituted C1-6 alkylene group or the like; and R4 represents an optionally substituted aryl group or the like), and Z represents a nitrogen atom or this general formula (CR6) (in the formula, R6 represents a hydrogen atom, a halogen atom, or an optionally substituted C1-12 alkyl group or the like)), or a salt thereof, exhibits excellent anti-HIV activity and is useful as an anti-HIV agent.

  由一般公式表示的杂环化合物（在公式中，R1、R2和R3可以相同也可以不同，每个表示氢原子、卤原子或这一般式（X1-Y1-R4）（在公式中：X1表示这一般式（NR5）（在公式中，R5表示氢原子等）或类似物；Y1表示可选择地取代的C1-6烷基链或类似物；R4表示可选择地取代的芳基或类似物），Z表示氮原子或这一般式（CR6）（在公式中，R6表示氢原子、卤原子或可选择地取代的C1-12烷基链或类似物）），或其盐，表现出优异的抗HIV活性，并可用作抗HIV剂。